Gero raises $17M for its AI aging-drug platform, bringing total equity to $34M

Gero

Gero raised $17M in new equity, with Melnichek Investments among the backers, taking its total to $34M. The round follows the Chugai licence and funds further work on its target-discovery platform. The company remains preclinical.

• New money: $17M; total equity raised: $34M
• Investors include Melnichek Investments and a co-founder of EPAM Systems
• Headquartered in Singapore with a US subsidiary in San Francisco
• Brian Kennedy, former Buck Institute head, sits on the board